SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-22-014092
Filing Date
2022-05-12
Accepted
2022-05-12 16:22:05
Documents
49
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vyne-20220331.htm   iXBRL 10-Q 789459
2 EX-31.1 vyne-20220331xexx311.htm EX-31.1 9706
3 EX-31.2 vyne-20220331xexx312.htm EX-31.2 9700
4 EX-32.1 vyne-20220331xexx321.htm EX-32.1 5280
5 EX-32.2 vyne-20220331xexx322.htm EX-32.2 5271
  Complete submission text file 0001628280-22-014092.txt   4025123

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vyne-20220331.xsd EX-101.SCH 27829
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vyne-20220331_cal.xml EX-101.CAL 50866
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vyne-20220331_def.xml EX-101.DEF 167815
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vyne-20220331_lab.xml EX-101.LAB 392602
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vyne-20220331_pre.xml EX-101.PRE 264004
43 EXTRACTED XBRL INSTANCE DOCUMENT vyne-20220331_htm.xml XML 501109
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38356 | Film No.: 22918159
SIC: 2834 Pharmaceutical Preparations